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and Zolta´n BodaaAQ1Womenwith antithrombin (AT) deficiency have an increased
risk for pregnancy-associated venous thromboembolism
(VTE) and adverse pregnancy outcome. AT deficiency is a
rare thrombophilia with heterogeneous genetic
background. Owing to the few cases reported in the
literature, management strategies of pregnancy with AT
deficiency are inconsistent. Our aim was to examine the
type of the genetic defect, management, maternal, and
pregnancy outcome in patients with hereditary AT
deficiency. Five expectant mothers with AT deficiency were
followed in our center to evaluate thrombotic events, and
maternal and pregnancy outcomes. AT gene sequencing
was performed in all cases, and levels of AT and anti-FXa
were regularly measured to guide the risk-adopted
anticoagulant prophylaxis. Three mothers had homozygous
type II heparin-binding site mutations and two had
heterozygous type I mutations of the gene encoding AT.
Two women had additional factor V Leiden heterozygous
mutations. Three maternal VTEs – four healthy newborns
and five pregnancy losses – were observed. The risk of
patients to VTE and adverse pregnancy outcome was found
to associate with the homozygous type II heparin-binding0957-5235 Copyright  2015 Wolters Kluwer Health, Inc. All rights reserved.site mutation of the AT gene. High risk of maternal VTE
and frequent pregnancy complications were observed to
associate with AT deficiency. Our results support the need
of individualized, risk-adopted anticoagulant therapy in
patients with AT deficiency. Blood Coagul Fibrinolysis
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Antithrombin (AT) is a natural anticoagulant and its
primary action is to inhibit thrombin-mediated fibrin clot
formation and generation of thrombin by FXa [1].
Antithrombin deficiency is a rare and the most thrombo-
genic type of thrombophilia, with a 25–50-fold increase
of relative risk of venous thromboembolism (VTE) in the
general population [1,2].
More than two hundred mutations of the AT gene have
been identified so far [3]. Mutations can cause defects in
the reactive site (type II RS), heparin-binding site (type
II HBS), or can generate a pleiotropic effect (type II
pulmonary embolism) [1,3–5]. Compared to type II RS
and pulmonary embolism deficiency, the defects of the
HBS are associated with a lower thrombotic diathesis and
can be present in the homozygous form [2,3,6,7]. A well
described type II HBS defect is known as Budapest
mutation [8]. The homozygous type II mutation with
low levels of antigen is associated with severe venous
and arterial thrombosis, and recurrent pregnancy loss
[1,6,7,9–16].In pregnant women with thrombophilia, especially with
AT deficiency, decreased activity of the anticoagulant
systemmay lead to deteriorated placental circulation and
adverse pregnancy outcome (APO) [6,17–19]. Maternal
AT deficiency has an estimated six-fold increased risk
of thromboembolic complications and a markedly
increased risk of fetal loss [6,20,21]. An increased risk
of late-pregnancy complications like preeclampsia, still-
birth, intrauterine growth restriction (IUGR), placental
abruption, and hemolysis, elevated liver enzymes and
low platelet count syndrome (HELLP) is also associated
with patients with AT deficiency and pregnancy [6,20,
22,23].
Treatment guidelines are inconsistent with regards to
management of patients with AT deficiency and preg-
nancy [24–27]. Owing to its rarity, therapeutic
approaches are mainly based on case reports published
in the literature [9,10,12,21–23,28–32]. The purpose of
our study was to evaluate management, and maternal and
fetal outcomes in patients with heritable AT deficiency
and pregnancy.DOI:10.1097/MBC.0000000000000348
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Study design and setting
A retrospective observational study was performed to
evaluate management, thrombotic events, maternal,
and pregnancy outcomes in women with hereditary AT
deficiency, managed in our center.
Study population
Between 2012 and 2014, five patients with hereditary AT
deficiency and pregnancy were included. Secondary
causes of AT deficiency were excluded. A written
informed consent was obtained from all patients accord-
ing to the rules of the local ethical committee.
Methods
Collection of data
We reviewed anamnestic data, medical history, infor-
mation regarding previous pregnancies, treatment before
and during pregnancy and postpartally, thrombotic
events, and maternal and fetal outcome.
Thrombophilia screening
Testing for factor V Leidenmutation and FII polymorph-
ism was performed and antiphospholipid antibodies were
screened in patients with a history of a previous VTE or
recurrent pregnancy loss. Protein C and S evaluations
were omitted in an attempt to prevent the possibility of a
false positive result.
Antithrombin gene sequencing
Collection of the clinical data involved thrombophilia
screening and genetic testing of the type of inheritance.
AT deficiency was confirmed by the fluorescent DNA
sequencing method.
Antithrombin measurements
Antithrombin activity measurements were performed
daily at the beginning of the therapy and were checked
monthly throughout pregnancy. AT activity was evalu-
ated just before (trough) and after 4 h of infusion (peak) of
AT concentrate (ATC). In cases one and two, Antith-
rombin III (Baxter, Vienna, Austria), and in cases three to
five Kybernin P (CSL Behring, Marburg, Germany) were
used. AT activity was assessed with heparin cofactor
assay, measuring FXa inhibition (Innovance AT, Sie-
mens, Germany). AT antigen was measured with the
immunonephelometric method (BN ProSpec system
AT-III, Siemens). The reference interval of AT activity
was 80–120% of the normal range [1].
Anti-FXa monitoring
Measurement of the low-molecular-weight heparin
(LMWH) levels was performed by using FXa and its
chromogenic substrate. Anti-FXa assessments were
performed daily at the beginning of therapy or in case
of dose adjustment, and were regularly monthly checked
throughout pregnancy [33]. Anti-FXa levels wereevaluated just before (trough) and 4 h after injection of
(peak) enoxaparin (Clexane, Sanofi, Miskolc, Hungary).
Reference ranges for themanagement of LMWH therapy
were defined as prophylactic (0.2–0.5 IU/ml) and thera-
peutic (0.5–1.2 IU/ml) [25,31,34].
Management protocol
Preconceptional period
Patients who were on acenocumarol or warfarin treatment
were immediately switched to enoxaparin. Women with-
out anticoagulant therapy were put on enoxaparin as soon
as their pregnancy test became positive. In one case,
anticoagulation started at the 23rd gestational week.
Gestation
Patients were checked monthly by a hemostasis-special-
ized hematologist in collaboration with an obstetrician
experienced in management of patients with pregnancy
and thrombophilia. Treatment protocol was based on the
patients’ thrombotic risk, described by the family history
of VTE, presence of a previous thromboembolic event,
and a history of APO [24,25,27,31,33,35,36]. The type of
inheritance was also taken into account; homozygous
type II ‘Budapest’ AT mutation was considered as a
factor resulting in a high risk for thrombotic events
[6,7,9,11–16]. Combined thrombophilia, like factor V
Leiden heterozygous mutation and AT deficiency, was
also considered as a high risk. In case of women with low
risk, 40mg of enoxaparin was given once a day at the start;
for high-risk patients, 1mg/kg body weight of enoxaparin
was prescribed twice a day in a form of a subcutaneous
injection [24,31,33,35,37]. LMWH administration was
guided by the measurements of anti-FXa levels, in
accordance with recommendations [24,33,35]. Our aim
was to reach prophylactic trough levels of anti-FXa in all
cases and to achieve therapeutic peak levels of anti-FXa
in women with a high thrombotic risk. If the targeted
anti-FXa level was not achieved despite increased dose of
enoxaparin, ATC was initiated [31,36,37]. Infusion of
ATC was started at a daily dose of 30–50 IU/kg body
weight [calculated from (100baseline activity)/1.6] to
achieve 100% of activity, as there are no general recom-
mendations or guidelines to monitor the treatment. For
maintenance, ATC was administered three times per
week. Trough and peak AT activity measurements were
regularly performed, but in fact, ATC dosing was guided
by anti-FXa activities (Table 1).
Delivery
At delivery, LMWH was withheld at least 12 h before
labor or cesarean section, and 30–50 IU/kg body weight
of ATC was given daily for 2 consecutive days.
Postpartum period
After postdelivery bleeding ended, 1mg/kg body weight
of enoxaparin was re-administered and switched to ace-
nocumarol or warfarin therapy. Patients with no history of
C
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Table 1 Clinical data of patients
Patient Age,
(gravity)
Parity Familiy
history
of VTE
VTE before
pregnancy
Risk Treatment
before
pregnancy
Treatment during pregnancy Treatment at delivery Treatment after
pregnancy
VTE during
pregnancy
Pregnancy
outcome
Maternal
outcome
Neonatal
outcome
1 21 [1] 1 negative DVT (left
iliocaval),
2005
Not
consi-dered
Acenocumarol Enoxaparin 30 mg OD, from
gw 6 from gw 8 enoxaparin
40 mg b.i.d. þ AT then ace-
nocoumarol
– Acenocumarol DVT at gw 7
(left iliofemoral,
right iliac)
gw 8 miscarriage Recovered Fetal death
(gw 8)
27 [2] High Acenocumarol Enoxaparin 50 mg b.i.d. þ
ATC 2500 IU OD then
1500 IU 3tw from gw 25t
ATC 2500 IU 3tw
LMWH was withheld 50
IU of ATC daily for two
days
Acenocumarol No gw 39 induced
vaginal delivery
Healthy Healthy,
(2840 g)
2 19 [1] 1 DVT None High None None – None No gw 19 miscarriage Healthy Fetal death
(gw 19)
20 [2] None None – None No gw 20 miscarriage Healthy Fetal death
(gw 20)
21 [3] None Enoxaparin 40 mg OD from
gw 11 40 mg enoxaparin
BID þ AT 1500 IU 2tw
– Enoxaparin 40 mg
b.i.d. for 6 weeks
No gw 28 miscarriage Healthy Fetal death
(gw 28)
22 [4] None Enoxaparin 60 mg b.i.d. from
gw 7 enoxaparin 50 mg from
gw 12 BIDþ ATC 2500 IU
3tw
LMWH was withheld 50
IU of ATC daily for two
days
Acenocumarol PE at gw 7 gw 32 preterm
delivery, prim.
caes.sec.
Healthy Healthy
(1640 g)
3 26 [1] 1 DVT None Low None Enoxaparin 40 mg OD then
BID, from gw 20 enoxaparin
60 mg BIDþ1000 IU ATC
2tw; from gw 26 2000 IU
3tw
LMWH was withheld 50
IU of ATC daily for two
days
Enoxaparin 60 mg
BID for six weeks
No gw 36 primary
ces. sec.
Healthy Healthy
(4140 g)
4 32 [1] 1 DVT DVT (left
calf), 2006
High None From gw 23 enoxaparin
80 mg BID
LMWH was withheld
30IU of ATC daily for
two days
Warfarin DVT (right
femoral)
at gw 23
gw 38 primary
cases. sec.
Recovered Healthy
(2640 g)
5 21 [1] 0 DVT DVT (bilat.
iliofemoral,
2009)
High Acenocumarol From gw 6 enoxaparin
40 mg BID þ2500 IU ATC
3tw
LMWH was withheld 50
IU of ATC daily for two
days
Acenocumarol No gw 13 miscarriage Healthy Fetal death
(gw 13)
2tw, two times weekly; 3tw, three times weekly; ATC, antithrombin concentrate; DVT, deep vein thrombosis; gw, gestational week; IU, International Unit; LMWH, low-molecular-weight heparin; mg, milligram; PE, pulmonary embolism;
VTE, venous thromboembolism.
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.VTE received 1mg/kg body weight of enoxaparin twice a
day for 6 weeks. In case of patients with previous or
gestational VTE, enoxaparin was switched to either
acenocumarol or warfarin (target INR 2.0–3.0).
Follow-up
Patients were monthly checked for 3 more months
postpartally.
Statistical analysis
Data are expressed as meanSD. Statistical analysis was
done with GraphPad Prism 5 software (GraphPad Soft-
ware Inc., San Diego, California, USA).
Results
A total of nine pregnancies of five women with hereditary
AT deficiency were reviewed. The women ranged in age
from 19 to 32 years [23.2 4.2 (meanSD)]. Four of the
five mothers were classified of being at high risk for a
thrombotic event. History of fetal loss was found in two
cases, and spontaneous abortion was observed, despite
heparin prophylaxis, in one case. All patients were put on
enoxaparin upon the recognition of pregnancy. Four
women required ATC to reach the targeted anti-FXa
effect (Table 1).
Laboratory findings
Three patients had homozygous type II HBS mutations
(Budapest 3), two had type I heterozygous mutations of
serpin peptidase inhibitor clade C1 (SERPINC1), and
two patients also had an additional factor V Leiden
heterozygous mutation. The patients with homozygous
type II mutations had seriously decreased AT levels
(12–17%). The targeted anti-FXa levels were attainable
except in one noncompliant case (third pregnancy of
case 3) (Table 2).
Discrepancies from treatment protocol
In one case, the patient was noncompliant, which
resulted in no further dose change in anticoagulant
therapy despite inappropriate anti-FXa effects. In
another case (patient 4), LMWH was started when the
patient presented with a right femoral deep vein throm-
bosis (DVT) and pregnancy in the 23rd gestational week.
In this case, assessments were performed monthly in the
local hospital due to the notable distance of the patient’s
home. Results were consulted by telephone.
Maternal outcome
Two mothers experienced VTE during pregnancy with-
out prophylaxis, including one nonmassive pulmonary
embolism and a right femoral DVT. One patient with
Budapest 3 homozygous ATmutation had aDVT despite
LMWH prophylaxis. All patients recovered. With ade-
quate anticoagulant therapy, no maternal VTE, pree-
clampsia, eclampsia, placental abruption, or HELLP
syndrome was observed. (Table 3)
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Table 3 Characteristics of pregnancies, maternal and neonatal
outcomes
Expectant mothers 5
Race Caucasian
Age at conception (years, meanSD) 20–32 (25.64.4)
Gravity 9
Pregnancy loss (without treatment) 3 (gestational week 8th,
19th, and 20th)
Pregnancy loss (under treatment) 2 (gestational week
13th and 28th)
Delivery 4
Type of delivery
Induced vaginal 1 (vacuum extraction)
Primary Ceserean section 3
Gestational age (weeks, meanSD) 363
Weight at birth (grams, meanSD) 28151028
VTE during pregnancy 3
DVT, deep vein thrombosis; VTE, venous thromboembolism.Neonatal outcome
Without effective anticoagulant prophylaxis, pregnancies
ended with one early and two late miscarriages in cases of
mothers with type II HBS AT mutations (Table 1).
Under anticoagulant therapy from six gestations, four
healthy babies were born – three at terminuses and
one at gestational week 32. The preterm delivery was
forced by the mother who denied further anticoagulant
therapy. Histology of the placenta found normal struc-
ture. Two fetal losses occurred on gestational weeks 13
and 28 in cases of two mothers with homozygous type II
HBS AT mutations, despite anticoagulant therapy.
Histology showed normal chorionic structure in case of
the early miscarriage. In contrast, examination of the
placenta revealed microthromboses and placental
degeneration in case of the late pregnancy loss. No IUGR
or stillbirth was observed (Table 3).
Discussion
In our study, on patients with AT deficiency and preg-
nancy, we experienced a high rate of maternal VTE,
especially in cases with homozygous type II HBS
mutations. Our data are in accordance with the citations
reporting that AT deficiency and pregnancy are associ-
ated with a high risk of VTE [20,22,32]. Our findings
suggest that the type of AT deficiency may play an
important role in creating a high-risk phenotype, as is
reported in cases of homozygous type II HBS mutations
[6,7,9–16], and may support the requirement of throm-
boprophylaxis in the prevention of maternal thrombotic
complications in patients with AT deficiency [24,26,
27,33].
In contrast to the literature reporting on the association of
thrombophilia and the risk of a poor pregnancy outcome
[20,38–40], systematic reviews found a conflicting
relationship [18,41], or even failed to find an association
between AT deficiency and APO [42,43]. Although AT
deficiency has a known heterogeneous genetic back-
ground configuring different phenotypes, the case seriesdid not differentiate between the types of AT
deficiencies and the levels of activity from the aspect
of risk of VTE and pregnancy outcomes. In one study,
authors did not find a relationship between AT activity
and pregnancy outcome, although the lowest AT activity
was 30% [31].
In the present study, mothers with the homozygous type
II HBSmutation and the lowest AT activity produced the
highest rates of miscarriage and maternal VTE. These
findings are in accordance with the case reports
[9,10,12,16] and support the notion that AT deficiency
increases the risk of placenta-mediated pregnancy com-
plications [20,29]. Adequate anticoagulant therapy may
prevent vascular lesions in the placenta caused by a
high-risk thrombophilia-like AT deficiency [9,20,23,
29–32,36]. Data concerning the association between late
pregnancy complications and AT deficiency are contra-
dictory [42,43]. Some authors reported a higher preva-
lence of AT deficiency among patients with late
pregnancy complications [20], which in the present study
were not observed.
Despite the fact that AT deficiency is considered as a
high-risk thrombophilia, treatment guidelines recom-
mend only antepartum and postpartum LMWH prophy-
laxis [25,26,33] or even just antenatal vigilance and
postpartum LMWH prophylaxis in cases of AT
deficiency without a history of maternal VTE [24]. These
guidelines classifying AT-deficient women into high or
moderately increased risk of VTE on the basis of family
and personal history of VTE do not differentiate between
the certain types and do not take into account the severity
in the decrease of AT activity [24,25]. In contrast, many
authors report on the association of high incidence of
maternal thrombotic and fetal complications in cases of
homozygous type II HBS AT deficiency and pregnancy
with a seriously diminished AT activity [9,10,12,16]. In
fact, we observed a strong association between the type
and severity of AT deficiency, and the incidence of
maternal and fetal complications. Our data underline
the clinical importance of the distinction between type
II HBS and other types of AT deficiencies, as well as
between the homozygous and the heterozygous forms.
Hence, when AT gene sequencing is not available, con-
comitant determination of progressive anti-FXa and
heparin cofactor anti-FXa activities can help to diagnose
the type II HBS AT deficiency and distinguish between
homozygotes and heterozygotes [44].
Although current guidelines do not recommend using
ATC even in high-risk patients with pregnancy requiring
therapeutic anticoagulation [24–26,45], many case
reports and observational studies found a better preg-
nancy outcome, with the use of LMWH and ATC
together [20,23,29–31,35–37,46,47]. Our data support
in conjunction with citations above the necessity of
therapeutic anticoagulation for high-risk patients.
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there are only two cases of homozygous type II HBS AT
deficiency with successful pregnancy outcome reported
until now [10,12]. This is the first study to report three
expectant mothers with homozygous type II HBS AT
mutations. They had two successful deliveries treated
with our anticoagulant protocol. The novel aspect of our
study is that a risk-adopted individualized anticoagulant
protocol was used on the basis of clinical risk assessment
and mutation analysis. The potential limitation of our
study could be its single-center design and a relatively
small number of cases due to the low prevalence of
AT deficiency.
We concluded that since the risk of thromboembolism
varies considerably between AT mutations, to assess
patients’ perceived level of risk – beyond the familiar
and personal VTE history – the type of AT deficiency
and the underlying mutation should be taken into
account. We found that AT deficiency is associated with
a high risk of maternal VTE and frequent pregnancy
complications, which support the need for risk-adopted
anticoagulant therapy.
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